• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Mls Capital Fund Ii Lp claimed ownership of 5,818,575 shares

    7/26/23 8:34:48 PM ET
    $GRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRNA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    MLS Capital Fund II LP

    (Last) (First) (Middle)
    SUITE 26.03, LEVEL 26, GTOWER
    199, JALAN TUN RAZAK

    (Street)
    KUALA LUMPUR N8 50400

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    05/29/2023
    3. Issuer Name and Ticker or Trading Symbol
    GreenLight Biosciences Holdings, PBC [ GRNA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    Officer (give title below) X Other (specify below)
    See remarks
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock, par value $0.0001 per share 5,818,575 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    The Reporting Person filed a Statement on Schedule 13D with the Securities and Exchange Commission on June 6, 2023, with respect to the shares reported herein. The Reporting Person may be deemed to be members of a "group" (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934 of persons that, in the aggregate, beneficially owned more than 10% of the Issuer's Common Stock. The filing of this Form 3 shall not be construed as an admission that the Reporting Person was a beneficial owner of more than 10% of any class of securities of the Issuer for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
    MLS Capital Fund II, L.P. By: MLSCF II (GP) (Labuan), LLP Its: General Partner By: /s/ Ganesh Kishore Title: Manager 07/26/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $GRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRNA

    DatePrice TargetRatingAnalyst
    12/8/2022$4.00Buy
    Canaccord Genuity
    10/14/2022$5.50Outperform
    Credit Suisse
    More analyst ratings

    $GRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GreenLight Announces Completion of Merger with Fall Line Endurance Fund

      LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced the closing of its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc. ("Parent"), pursuant to which Merger Sub merged with and into GreenLight with GreenLight surviving as a wholly-owned subsidiary of Parent (the "Merger"). Following the completion of the Merger, shares of GreenLight common stock, par value $0.0001 per share, and GreenLight warrants ceased trading on the NASDAQ Global Market (the "NASDAQ") before market open on July 24, 2023, and will no longer be listed for trading on the NASDAQ. Each r

      7/24/23 9:49:15 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares

      LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (

      7/20/23 8:06:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of GRNA, AAIC, EMBK, and REUN

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of GRNA to a group of buyers led by Fall Line Capital, LLC for $0.30 per share in cash. If you are a GRNA investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at [email protected]. Arlington Asset Investment Corp. (NYSE:AAIC) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connect

      6/3/23 8:17:00 PM ET
      $AAIC
      $EMBK
      $GRNA
      $REUN
      Real Estate Investment Trusts
      Real Estate
      Computer Software: Prepackaged Software
      Technology

    $GRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Kodiak Venture Partners Iii Lp

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:55:29 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Kodiak Venture Partners Iii Lp claimed ownership of 9,809,895 shares

      3 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:48:26 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Clarke Dennis A.

      4 - GreenLight Biosciences Holdings, PBC (0001822691) (Issuer)

      7/27/23 10:25:48 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on GreenLight Biosciences with a new price target

      Canaccord Genuity initiated coverage of GreenLight Biosciences with a rating of Buy and set a new price target of $4.00

      12/8/22 9:11:51 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse initiated coverage on GreenLight Biosciences with a new price target

      Credit Suisse initiated coverage of GreenLight Biosciences with a rating of Outperform and set a new price target of $5.50

      10/14/22 7:27:11 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Financials

    Live finance-specific insights

    See more
    • GreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding Shares

      LEXINGTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- GreenLight Biosciences Holdings, PBC (NASDAQ:GRNA) ("GreenLight" or the "Company") today announced that it is initiating the final steps in closing its previously announced merger with SW MergerCo, Inc. ("Merger Sub") and SW ParentCo, Inc ("Parent"). Following the completion of the Merger, shares of GreenLight common stock are expected to cease trading on the NASDAQ Global Market ("NASDAQ") after market close on July 20, 2023, and will no longer be listed for trading on the NASDAQ. Merger Sub's tender offer (the "Offer") to purchase any and all outstanding shares of GreenLight's common stock (other than shares of GreenLight common stock (

      7/20/23 8:06:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    SEC Filings

    See more
    • SEC Form 15-12G filed by GreenLight Biosciences Holdings PBC

      15-12G - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      8/11/23 9:00:27 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GreenLight Biosciences Holdings PBC filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (Amendment)

      8-K/A - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      7/28/23 9:02:32 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by GreenLight Biosciences Holdings PBC

      EFFECT - GreenLight Biosciences Holdings, PBC (0001822691) (Filer)

      7/26/23 12:15:07 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/28/23 4:25:26 PM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/28/23 10:54:08 AM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by GreenLight Biosciences Holdings PBC (Amendment)

      SC 13D/A - GreenLight Biosciences Holdings, PBC (0001822691) (Subject)

      7/27/23 4:24:26 PM ET
      $GRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care